AU2001249835A1 - Diagnosis and treatment of alzheimer's disease - Google Patents

Diagnosis and treatment of alzheimer's disease

Info

Publication number
AU2001249835A1
AU2001249835A1 AU2001249835A AU4983501A AU2001249835A1 AU 2001249835 A1 AU2001249835 A1 AU 2001249835A1 AU 2001249835 A AU2001249835 A AU 2001249835A AU 4983501 A AU4983501 A AU 4983501A AU 2001249835 A1 AU2001249835 A1 AU 2001249835A1
Authority
AU
Australia
Prior art keywords
alzheimer
diagnosis
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249835A
Inventor
Kathryn L. Durham
David L. Friedman
Herath Mudiyanselage Athula Chandrasiri Herath
Lida H. Kimmel
Rajesh Bhikhu Parekh
David M. Potter
Christian Rohlff
B. Michael Silber
Thomas R. Stiger
P. Trey Sunderland
Robert Reid Townsend
Frost White
Stephen A. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Pfizer Inc
Original Assignee
Oxford Glycosciences UK Ltd
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd, Pfizer Inc filed Critical Oxford Glycosciences UK Ltd
Publication of AU2001249835A1 publication Critical patent/AU2001249835A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
AU2001249835A 2000-04-03 2001-04-03 Diagnosis and treatment of alzheimer's disease Abandoned AU2001249835A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19450400P 2000-04-03 2000-04-03
US60/194,504 2000-04-03
US25364700P 2000-11-28 2000-11-28
US60/253,647 2000-11-28
PCT/US2001/010908 WO2001075454A2 (en) 2000-04-03 2001-04-03 Diagnosis and treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2001249835A1 true AU2001249835A1 (en) 2001-10-15

Family

ID=26890092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249835A Abandoned AU2001249835A1 (en) 2000-04-03 2001-04-03 Diagnosis and treatment of alzheimer's disease

Country Status (5)

Country Link
US (2) US20020164668A1 (en)
EP (1) EP1325338A2 (en)
JP (1) JP2004505609A (en)
AU (1) AU2001249835A1 (en)
WO (1) WO2001075454A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198950A1 (en) * 2001-04-30 2004-10-07 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
US6599877B2 (en) * 2001-04-30 2003-07-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons
US6627606B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons
US7008800B2 (en) * 2001-04-30 2006-03-07 Artemis Proteomics, Ltd. Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
US6627608B2 (en) 2001-04-30 2003-09-30 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
US7015004B2 (en) * 2001-11-23 2006-03-21 Syn X Pharma, Inc. Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
US20020160423A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1536 daltons
US6890763B2 (en) 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
US20020160420A1 (en) * 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
EP1408333A3 (en) * 2001-10-03 2006-10-25 Pfizer Products Inc. Diagnosis and treatment of Alzheimer's disease
WO2003032894A2 (en) * 2001-10-12 2003-04-24 Pfizer Products Inc. Method of monitoring neuroprotective treatment
US7132244B2 (en) 2001-11-21 2006-11-07 Syn X Pharma, Inc. Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
US7314762B2 (en) 2001-11-21 2008-01-01 Nanogen, Inc. Apolipoprotein biopolymer markers indicative of insulin resistance
US7026129B2 (en) * 2001-11-23 2006-04-11 Syn X Pharma, Inc. IG lambda biopolymer markers predictive of Alzheimers disease
US7125678B2 (en) * 2001-11-23 2006-10-24 Nanogen, Inc. Protein biopolymer markers predictive of type II diabetes
US20030100009A1 (en) * 2001-11-23 2003-05-29 George Jackowski Inter alpha trypsin inhibitor biopolymer markers indicative of insulin resistance
JP2005510722A (en) * 2001-11-23 2005-04-21 シン．クス ファーマ、インコーポレイテッド PEDF biopolymer marker to predict Alzheimer's disease
US7179605B2 (en) * 2001-11-23 2007-02-20 Nanogen Inc. Fibronectin precursor biopolymer markers indicative of alzheimer's disease
US7074576B2 (en) * 2001-11-23 2006-07-11 Syn X Pharma, Inc. Protein biopolymer markers indicative of alzheimer's disease
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030113808A1 (en) * 2001-12-13 2003-06-19 George Jackowski Apolipoprotein biopolymer markers predictive of alzheimers disease
ATE261126T1 (en) 2002-08-01 2004-03-15 Mtm Lab Ag PROCEDURE FOR SOLUTION-BASED DIAGNOSIS
CA2745569C (en) * 2002-08-23 2015-07-14 Bayer Schering Pharma Aktiengesellschaft Biomarkers for diagnosing alzheimer`s disease
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
CA2519129A1 (en) * 2003-03-18 2004-09-30 Biovision Ag Method for detecting alzheimer's disease and corresponding peptides and detection reagents
US8597911B2 (en) * 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
WO2005041887A2 (en) * 2003-10-29 2005-05-12 The Johns Hopkins University Pigment epithelium-derived factor, novel biological activity and methods of use
EP1730170B1 (en) 2004-03-10 2020-02-19 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subject
KR101155740B1 (en) 2004-03-31 2012-06-12 톳쿄기쥬츠 가이하츠 가부시키가이샤 Epithelial cell growth promoter
WO2006005591A1 (en) * 2004-07-12 2006-01-19 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
WO2006029838A2 (en) * 2004-09-14 2006-03-23 Geneprot Inc. Secreted polypeptide species involved in alzheimer’s disease
WO2006074787A2 (en) * 2004-12-27 2006-07-20 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
WO2006069739A2 (en) * 2004-12-27 2006-07-06 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
US20080307537A1 (en) * 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
CN101198698B (en) * 2005-03-31 2014-03-19 中外制药株式会社 Process for production of polypeptide by regulation of assembly
US8546323B2 (en) * 2005-06-24 2013-10-01 Ramtin Agah Thrombospondin-1 derived peptides and treatment methods
US20080207498A1 (en) * 2005-09-06 2008-08-28 Bodie Neil M Methods for Treating Alzheimer's Disease
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
RU2432362C2 (en) * 2005-11-30 2011-10-27 Эбботт Лэборетриз Monoclonal antibodies and applications thereof
US20070166765A1 (en) * 2006-01-16 2007-07-19 Christian Rohlff Protein isoforms and uses thereof
CA2647846C (en) * 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3345616A1 (en) * 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN106519025B (en) 2007-09-26 2021-04-23 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
KR101922788B1 (en) 2007-09-26 2018-11-27 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010107109A1 (en) 2009-03-19 2010-09-23 中外製薬株式会社 Antibody constant region variant
JP5837821B2 (en) 2009-09-24 2015-12-24 中外製薬株式会社 Antibody constant region variants
JP5889181B2 (en) 2010-03-04 2016-03-22 中外製薬株式会社 Antibody constant region variants
MX336196B (en) 2010-04-15 2016-01-11 Abbvie Inc Amyloid-beta binding proteins.
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
WO2012067176A1 (en) 2010-11-17 2012-05-24 中外製薬株式会社 Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CA2819530C (en) 2010-11-30 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9839671B2 (en) 2012-01-13 2017-12-12 The University Of Birmingham Peptide and uses therefor
GB2515334A (en) * 2013-06-20 2014-12-24 Neuro Bio Ltd Biomarkers for alzheimer's Disease
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
CN105334300A (en) * 2014-08-01 2016-02-17 沈德铭 Rapid method for screening treatment effectiveness of biological source substance
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
EP3654038A4 (en) 2017-07-13 2021-03-03 Mcbi Inc. Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker
CN113111874A (en) * 2021-04-01 2021-07-13 上海市第一人民医院 Rapid classification method for lateral images of lumbar vertebrae

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US5272055A (en) * 1991-12-24 1993-12-21 The University Of Kentucky Research Foundation Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method
US5429947A (en) * 1992-06-17 1995-07-04 Merril; Carl R. Diagnosing Alzheimer's disease and schizophrenia
CA2218599A1 (en) * 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same
WO1998036062A1 (en) * 1997-02-13 1998-08-20 Smithkline Beecham Plc Neural cell adhesion molecule splicing variants
AU6465798A (en) * 1997-03-14 1998-09-29 Neuromark Diagnosing neurologic disorders
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors

Also Published As

Publication number Publication date
WO2001075454A3 (en) 2003-05-08
JP2004505609A (en) 2004-02-26
WO2001075454A2 (en) 2001-10-11
EP1325338A2 (en) 2003-07-09
US20020164668A1 (en) 2002-11-07
US20070015217A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
HUP1500560A2 (en) Thioflavin derivatives and their use in diagnosis and treatment of alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
HUP0103654A2 (en) Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002239765A1 (en) Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
AU2002302238A1 (en) A method of treatment of alzheimer's disease and device therefor
AU2003248660A1 (en) Treatment of vascular dysfunction and alzheimer's disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
AU2002312667A1 (en) Individualization of therapy with alzheimer's disease agents
PL377110A1 (en) Prevention and treatment of alzheimer's disease
GB9908059D0 (en) Diagnosis and treatment of diseases
AU2001253024A1 (en) Diagnosis and treatment of gastrointestinal disease
AU2002319591A1 (en) Diagnosis and treatment of vascular disease
GB0008162D0 (en) Diagnosis and treatment of alzheimer's disease
AU2002312797A1 (en) Peptide for the diagnosis and therapy of alzheimer's disease